Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Immutep Ltd ADR (IMMP)

Immutep Ltd ADR (IMMP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 51,728
  • Shares Outstanding, K 147,372
  • Annual Sales, $ 6,690 K
  • Annual Income, $ -39,780 K
  • EBIT $ 0 M
  • EBITDA $ -37 M
  • 60-Month Beta 1.77
  • Price/Sales 7.71
  • Price/Cash Flow N/A
  • Price/Book 0.80
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 08/29/25
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 266.81% (-349.78%)
  • Historical Volatility 495.26%
  • IV Percentile 67%
  • IV Rank 17.14%
  • IV High 1,253.85% on 02/12/26
  • IV Low 62.69% on 10/03/25
  • Expected Move (DTE 16) 1.8700 (532.76%)
  • Put/Call Vol Ratio 3.33
  • Today's Volume 13
  • Volume Avg (30-Day) 169
  • Put/Call OI Ratio 0.07
  • Today's Open Interest 5,097
  • Open Int (30-Day) 5,047
  • Expected Range 0.0000 to 2.2210

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3433 +5.30%
on 03/31/26
2.7750 -86.97%
on 03/05/26
-2.4385 (-87.09%)
since 02/27/26
3-Month
0.3433 +5.30%
on 03/31/26
3.2300 -88.81%
on 01/26/26
-2.4985 (-87.36%)
since 12/31/25
52-Week
0.3433 +5.30%
on 03/31/26
3.5299 -89.76%
on 12/08/25
-1.4085 (-79.58%)
since 04/01/25

Most Recent Stories

More News
IMMP Investor Alert: Immutep Ltd. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Concealed Trial Futility: Levi & Korsinsky

Immutep Stock Collapsed Up to 90% After Independent Committee Recommended Halting Lead Phase III Trial -- Levi & Korsinsky Investigates Potential Securities Law Violations

IMMP : 0.3615 (+2.99%)
Rosen Law Firm Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation - IMMP

NEW YORK , March 30, 2026 /PRNewswire/ -- 

IMMP : 0.3615 (+2.99%)
Lost Money on Immutep Limited (IMMP)? Possible Fraud - Contact Levi & Korsinsky Today

New York, New York--(Newsfile Corp. - March 30, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Immutep Limited ("Immutep Limited") (NASDAQ: IMMP) concerning potential...

IMMP : 0.3615 (+2.99%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immutep Limited - IMMP

NEW YORK , March 26, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Immutep Limited ("Immutep" or the "Company") (NASDAQ: IMMP).  Such investors are advised...

IMMP : 0.3615 (+2.99%)
IMMP Investor Alert: Immutep Ltd. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Concealed Trial Futility: Levi & Korsinsky

Immutep Stock Collapsed Up to 90% After Independent Committee Recommended Halting Lead Phase III Trial -- Levi & Korsinsky Investigates Potential Securities Law Violations

IMMP : 0.3615 (+2.99%)
Rosen Law Firm Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation - IMMP

NEW YORK , March 24, 2026 /PRNewswire/ --

IMMP : 0.3615 (+2.99%)
Fraud Investigation: Levi & Korsinsky Investigates Immutep Limited (IMMP) on Behalf of Shareholders

New York, New York--(Newsfile Corp. - March 23, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Immutep Limited (NASDAQ: IMMP) ("Immutep Limited") concerning potential...

IMMP : 0.3615 (+2.99%)
IMMP Investors Have Opportunity to Join Immutep Limited Fraud Investigation with the Schall Law Firm

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Immutep Limited (“Immutep” or “the Company”) (NASDAQ:...

IMMP : 0.3615 (+2.99%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immutep Limited - IMMP

NEW YORK , March 19, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Immutep Limited ("Immutep" or the "Company") (NASDAQ: IMMP).  Such investors are advised...

IMMP : 0.3615 (+2.99%)
Rosen Law Firm Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation - IMMP

NEW YORK , March 18, 2026 /PRNewswire/ --

IMMP : 0.3615 (+2.99%)

Business Summary

Immutep Limited is a biotechnology company. It engaged in developing novel immunotherapy treatments for cancer and autoimmune disease. The company's product pipeline consists of eftilagimod alpha, IMP731, IMP701 and IMP761 which are in clinical stage. It operates primarily in Europe, Australia and the...

See More

Key Turning Points

3rd Resistance Point 0.3816
2nd Resistance Point 0.3724
1st Resistance Point 0.3617
Last Price 0.3615
1st Support Level 0.3418
2nd Support Level 0.3326
3rd Support Level 0.3219

See More

52-Week High 3.5299
Fibonacci 61.8% 2.3126
Fibonacci 50% 1.9366
Fibonacci 38.2% 1.5606
Last Price 0.3615
52-Week Low 0.3433

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.